65851-97-0

Upstream product

• 33924-48-0 methyl 5-chloro-2-methoxybenzoate 
• 66237-57-8 3-bromo-5-chloro-2-methoxybenzoic acid 
• 74-88-4 methyl iodide 
• 4068-58-0 3-bromo-5-chloro-2-hydroxy benzoic acid 

Downstream Products

• 871339-01-4 1,1-dimethylethyl 4-[5-chloro-3-({[2-(dimethylamino)ethyl]amino}carbonyl)-2-(methyloxy)phenyl]piperazine-1-carboxylate 
• 871339-00-3 5-chloro-3-(4-{[(1,1-dimethylethyl)oxy]carbonyl}piperazin-1-yl)-2-(methyloxy)benzoic acid 
• 871339-06-9 1,1-dimethylethyl 4-[5-chloro-3-[(dimethylamino)methyl]-2-(methoxy)phenyl]piperazine-1-carboxylate 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND

Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER

The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, Non-Alcholic Fatty Liver Disease (NAFLD), Non-Alcholic Steathohepatitis (NASH), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.

NEW COMPOUNDS II

Compounds of formula I, wherein Y = H, -OH, halo, -OC1-6alkyl, -C1-6alkyl, the two latter optionally substituted with halo, -CN, -OH, -CF3, -NH2; Rl = -C3-6cycloaUcyl, heterocycloalkyl, aryl, alkylaryl, heteroaryl, -C3-6-alkyl, optionally substituted with halo, -CN, -OH, -CF3, -OCF3, -NH2, -CONH2; M = -C(O)-, -C(H2)-, -CH(OR3)-, -N(Ra)-, -S(O)r-, heteroaryl and a bond; wherein Ra = H or C1-6alkyl and r = 0, 1 or 2; R2 = H, halo, -CN, or D = -C1-6alkyl, C3-6cycloalkyl, heterocycloalkyl, -N(CH3)2, aryl, alkylaryl, heteroaryl, and heterocyclic groups; where D is optionally substituted with G = halo, -NO2, -CN, -OH, -CF3, -OCF3, -NH2, -CONH2, -COOH, aryl, heteroaryl, heterocyclic groups, -C1-6alkyl, -C1-6alkoxy, heterocycloalkyl, and C1-6alkylcarboxylate; where D may be connected to G by L = -C(O)-, -S-, or -S(O2)-; and G may be further substituted with substituents selected from halo, -NO2, -CN, -OH, -CH3, -OCH3, -CF3, -OCF3, -NH2, -CONH2, -COOH, C1-6alkylcarboxylate; and R3 = -OH or C1-6alkoxy.